You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 18, 2024

CLINICAL TRIALS PROFILE FOR OTEZLA


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for otezla

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00521339 ↗ Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis Completed Amgen Phase 2 2007-08-01 The study will test the safety and tolerability of Apremilast twice a day in participants with recalcitrant plaque type psoriasis.
NCT00521339 ↗ Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis Completed Celgene Corporation Phase 2 2007-08-01 The study will test the safety and tolerability of Apremilast twice a day in participants with recalcitrant plaque type psoriasis.
NCT00773734 ↗ Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study) Completed Amgen Phase 2 2008-09-01 The purpose of this study was to test if the drug apremilast was safe, if it helped improve psoriasis, and how well the participants tolerated it.
NCT00773734 ↗ Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study) Completed Celgene Corporation Phase 2 2008-09-01 The purpose of this study was to test if the drug apremilast was safe, if it helped improve psoriasis, and how well the participants tolerated it.
NCT00866359 ↗ A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease Completed Amgen Phase 2 2009-08-01 The purpose of this study is to assess whether Apremilast is safe and effective in the treatment of patients with Behcet Disease.
NCT00866359 ↗ A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease Completed Celgene Corporation Phase 2 2009-08-01 The purpose of this study is to assess whether Apremilast is safe and effective in the treatment of patients with Behcet Disease.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for otezla

Condition Name

Condition Name for otezla
Intervention Trials
Psoriasis 11
Plaque Psoriasis 10
Psoriatic Arthritis 6
Behcet Syndrome 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for otezla
Intervention Trials
Psoriasis 26
Arthritis 9
Arthritis, Psoriatic 8
Dermatitis 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for otezla

Trials by Country

Trials by Country for otezla
Location Trials
United States 267
Canada 49
Australia 15
Germany 15
Japan 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for otezla
Location Trials
California 19
Florida 16
New York 15
Texas 13
Illinois 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for otezla

Clinical Trial Phase

Clinical Trial Phase for otezla
Clinical Trial Phase Trials
Phase 4 17
Phase 3 13
Phase 2 15
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for otezla
Clinical Trial Phase Trials
Completed 21
Recruiting 14
Not yet recruiting 4
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for otezla

Sponsor Name

Sponsor Name for otezla
Sponsor Trials
Amgen 23
Celgene Corporation 19
Celgene 9
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for otezla
Sponsor Trials
Industry 55
Other 52
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.